Royal College of Surgeons in Ireland Coláiste Ríoga na Máinleá in Éirinn Building on our heritage in surgery, we will enhance human health through endeavour, innovation and collaboration in education, research and service. APPOINTMENTS Professor and Head of Department of Pharmaceutical & Medicinal Chemistry Information Schedule KEY DATES Applications Open: 1st November 2012 Closing date for applications: Friday, December 7th 2012 Interviews: January 2013 Appointment timeline: Mid 2013
Transcript
Royal College of Surgeons in Ireland Coláiste Ríoga na Máinleá in Éirinn
Building on our heritage in surgery, we will enhance human health through endeavour, innovation
and collaboration in education, research and service.
APPOINTMENTS
Professor and Head of Department of Pharmaceutical & Medicinal Chemistry
Information Schedule KEY DATES Applications Open: 1st November 2012 Closing date for applications: Friday, December 7th 2012 Interviews: January 2013 Appointment timeline: Mid 2013
1 About RCSI
Established in 1784, the Royal College of Surgeons in Ireland (RCSI) is an independent, not-for-profit, health sciences
institution with a unique international perspective from its headquarters in Dublin and its presence on three continents. Its
original purpose was to train surgeons and set national standards for surgery in Ireland. Today RCSI has a wide portfolio of
undergraduate and postgraduate academic and professional courses. Its undergraduate medical school is the largest in
Ireland. In Dublin RCSI educates a substantial cohort of international alongside Irish and other EU students. To remain
competitive in an international market by providing an internationally recognised and respected medical and health sciences
qualifications and careers, RCSI continually invests in elevating educational standards, innovation and facilities.
1.1 Our campuses
More than 60 countries are represented in RCSI’s international student body.
In Dublin there are over 3,000 students from approximately 50 countries and approximately 800 staff. RCSI is based in
the heart of Dublin city – a unique city centre campus in one of Europe’s capital cities. The College has a strong
international presence with Schools in Bahrain,
Malaysia and Dubai.
In Bahrain, the College established a medical
university, the RCSI Medical University of Bahrain
(MUB) in 2004. MUB provides a full spectrum of
undergraduate courses in Medicine, Nursing &
Midwifery and postgraduate courses in Nursing,
Healthcare Ethics & Law and Healthcare
Leadership to over 1,000 students annually.
Students on these courses come from Bahrain, the
Gulf Region and beyond.
In Dubai RCSI’s Institute of Leadership run
postgraduate courses in healthcare management
and leadership for experienced healthcare
professionals.
In Malaysia, RCSI has run Penang Medical
College in association with University College
Dublin, since 1995. This is a ‘twinning’ model
where mostly Malaysian medical students complete the first half of their training in Ireland and then return to complete
their studies, based on an Irish curriculum, in Penang. By 2013, over 1,000 medical students will have graduated from
this programme. From 2011, RCSI extended its long-standing educational involvement with Malaysia when it established
an undergraduate medical programme in Kuala Lumpur, as a partner to Perdana University. The first group of Perdana
students, studying the RCSI curriculum delivered mainly by RCSI specialist academic staff, commenced in Autumn 2011.
Graduates of medicine across all of RCSI’s campuses complete rigorously evaluated programmes that allow for a
common degree award of RCSI and the National University of Ireland.
The medical school in RCSI is one of the world’s leading international medical schools. Its curriculum is international as
attested to by the fact that it is accredited by medical and educational regulators on three continents - Europe (Ireland),
Middle East (Bahrain) and Far East (Malaysia). RCSI runs the traditional European format undergraduate programme of 5
years (6 years if the Foundation Year is included) and also runs Ireland’s first graduate entry programme (a four year
programme based on the North American medical education model). A bespoke foundation programme (the Medical
Commencement Programme) is also provided to high achieving international students who need to further develop their
professional English language and/or basic sciences skills.
The College also provides undergraduate courses in pharmacy, physiotherapy and nursing. In Dublin, RCSI provides a three
or four year Pharmacy degree (depending on intake qualifications) followed by an obligatory one year internship culminating
in an MPharm degree for which RCSI is the national provider in Ireland, i.e. all Pharmacy graduates in Ireland complete
their MPharm at RCSI. A similar three or four year programme is provided in Physiotherapy. A four year undergraduate
Nursing programme is provided in RCSI Bahrain, with Nurse Bridging Programmes delivered in both Dublin and Bahrain to
nurses who have qualified previously through diploma level programmes and wish to progress to complete a degree in
nursing.
2.2 Postgraduate Training
RCSI delivers postgraduate education and professional training through the School of Postgraduate Studies and the Institute of
Leadership; through its Faculties of Radiology, Dentistry, Nursing, and Sports & Exercise Medicine and through the National
Surgical Training Centre. Postgraduate degrees include taught masters programmes in Surgical Training, Medicine, Pharmacy,
Physiotherapy, Leadership and Nursing.It also provides research-focused MD and PhD degrees, with many of the PhD
students in one of several structured PhD programmes in Biomedical Sciences or Population & Health Services Research.
RCSI provides the national training programmes for specialties such as Surgery and Radiology. It also provides opportunities
for continuous professional development and for meeting ongoing professional and regulator training needs. RCSI’s unique
portfolio of involvement in undergraduate and postgraduate health professional education and training means that aspects
pertinent to one part of the professional career can be matched to aspects in another (e.g. targeting early training to clinical and
academic needs of later aspects of careers).
2.3 Research Institute
The RCSI Research Institute is one of Ireland’s foremost research centres. RCSI is committed to performing high levels of
research activity, to commercialising intellectual property arising from its research, and to developing collaborative links with
industry, educational and research institutions both nationally and internationally. Reflecting its unique healthcare focus, its
research theme is Translational Health Research: - “from bench to bedside to population”. RCSI built Ireland’s first Clinical
Research Centre on a hospital campus in 2000, alongside Beaumont Hospital and Connolly Hospital, its main teaching
hospitals in Dublin. This supports its translational research focus and provides ready opportunities for clinician-based
research studies. The main clusters in RCSI’s Research Strategy are: cancer; neuroscience; respiratory and cardiovascular
diseases; infection, inflammation & immunity; bioengineering & regenerative medicine; population health sciences &
healthcare delivery.
3 Strategic Plan RCSI holds a distinctive position in the Irish third-level education landscape, with a number of unique attributes:
A singular institutional focus on healthcare education and research
An unrivalled international presence in healthcare education
A long-standing engagement in life-long learning, as the national agency responsible for surgical and other
postgraduate specialty training
A strong record of innovation in teaching and learning, focused on a high quality student experience
A distinctively entrepreneurial culture, by virtue of the need to be self-sufficient in an international marketplace, and
as a not-for-profit organisation, with minimal dependence on the State
3.1 RCSI’s Mission
“To educate, nurture and discover for the benefit of human health” “To educate” - The primary function of RCSI is to empower and facilitate its students, to optimise their futures as healthcare
professionals and scientists.
"The central task of education is to implant a will and facility for learning; it should produce not learned but learning
people" ~Eric Hoffer
“nurture” - RCSI aims to do more for its students than impart knowledge. We aim to care for, encourage, challenge and
motivate them to realise their full potential.
“and discover” - RCSI’s aspiration is to deliver impact in research which, coupled with education, is at the core of RCSI
activities.
“for the benefit of human health” - The end beneficiary of the College’s work in education and research are people and
patients everywhere. The term “human health” is all-encompassing and sufficiently conveys RCSI’s aspiration to advance
healthcare provision not just at its bases nationally but also globally through its graduates and its research.
3.2 RCSI’s Vision
“To be recognised internationally as a leading centre for professional education, research and innovation in healthcare”
“recognised internationally” RCSI’s ambition is to be a globally identifiable respected brand by its peers in third level
education, its clinical partners and employers of its graduates and prospective students
“a leading centre” RCSI aims to be synonymous with excellence as measured by the strength of student demand, the
quality of its graduates and the impact of its research
“for professional education, research and innovation in healthcare” RCSI curricula are outcome focussed. Graduates
are ready to perform to the highest professional standards and RCSI research is impactful – achieving high levels of
citations by others.
3.3 RCSI’s Values
RCSI’s shared values are reflected in all College policies and
procedures, to create an environment of trust and mutual
understanding.
The core RCSI values are:
Respect – we commit to transparency, integrity and respect for all
persons who engage with RCSI including students, staff, patients and
the general public.
Collegiality – we provide a nurturing, social and inclusive community
conducive to collaboration and development.
Scholarship – we provide a stimulating and challenging environment
that promotes excellence in teaching and learning.
Innovation – we foster a culture of discovery to create research with
impact and an entrepreneurial energy, balanced with disciplined financial stewardship to secure our independence.
4 RCSI’s Governance Structure
RCSI is governed by a Council. As it is both an independent degree-awarding institution and a surgical Royal
College, two high-level Boards govern these domains of activity in parallel (as depicted below):
The Medicine & Health Sciences Board (MHSB) is the governing body responsible for all degree-
awarding educational activities of RCSI
The Surgical & Postgraduate Faculties Board (SPFB) is the governing body responsible for the
postgraduate training, competence assurance and professional examination activities of RCSI
FACULTIES
5 Pharmaceutical & Medicinal Chemistry at RCSI
Chemistry in RCSI goes back a long way - the first Professor of Chemistry, John Apjohn, having been appointed in 1828 (-
1850). The Department is responsible for undergraduate Chemistry teaching in the Schools of Pharmacy, Medicine and
Physiotherapy as well as postgraduate teaching in the School of Pharmacy and in structured PhD programmes. The
staff complement is 6 academic staff, 2 technicians, 2 secretaries, 4 postdoctoral research fellows, 2 senior
demonstrators and there are also 24 postgraduate and 3 ERASMUS students.
The Department is very research active and its research is aligned with the RCSI Research Strategy (currently under
revision) in interdisciplinary translational research. It currently has research programmes in the following areas:
Organic synthesis/methodology underpinning drug discovery.
Peptide-based antibiotic and anticancer agents, nanomedicines and drug delivery systems.
Synthesis and pharmacological evaluation of metal-based anti-cancer agents.
New inhibitors of cyclooxygenase as anti-inflammatory agents.
Drugs from natural sources.
The Department is part of The Centre for Synthesis and Chemical Biology, http://www.ucd.ie/cscb/, a major research
collaboration in the chemical sciences between RCSI, University College Dublin (UCD) and Trinity College Dublin (TCD) and
funded under the Irish Government Programme for Research in 3rd Level Institutions, Cycle 3. It is also a key participant
with UCD, TCD and University College Cork (UCC) in the Science Foundation Ireland (SFI) Strategic Research Cluster ‘The
Irish Drug Delivery Network’: http://www.ucd.ie/iddn/. Members of the Department publish in leading international
journals (see selected publications in Section 8). They are also highly successful in securing competitive national and EU
funding (e.g. in the SFI Research Frontiers Programme 2011 the Department received 3 major awards) and in
commercialising IP generated by their research, e.g. one member of staff has formed a ‘spin-off’ company, another has
licensed technology to a pharmaceutical company and several patents have been filed. Members of the Department have
won a number of RCSI and National awards for their teaching and research (see under Staff on website). The Department
has a large number of research collaborations. These are with other research groups in RCSI and with groups at: the
Institute of Biophysics, Brno; the CNR Institute of Crystallography, Bari; the Universities of Sydney, Debrecen, Ljubljana,
Florence, Naples (Federico II), Bologna, Siena, Genoa, Limerick, Dublin City, Galway; UCD, TCD, UCC and the Institute of
Technology, Tallaght.
The Department is involved in undergraduate teaching programmes in the Schools of Pharmacy (Years 1-4), Medicine
(Foundation Year) and Physiotherapy (Foundation Year). It also contributes modules to the MSc in Industrial
Pharmaceutical Sciences and to the Structured PhD Programmes on ‘Diagnostics & Therapeutics for Human Disease’,
‘Bioanalysis & Therapeutics’ and ‘Drug Discovery & Delivery’.
For further information on the Department of Pharmaceutical & Medicinal Chemistry see:
http://www.rcsi.ie/index.jsp?p=248&n=265
6 Job Description
Job Title: Professor and Head of Department of Pharmaceutical & Medicinal
Location: Department of Pharmaceutical & Medicinal Chemistry, RCSI, 123 St Stephen’s Green
Reporting to: Dean of the Faculty of Medicine & Health Sciences
Timeframe: This is a full-time, permanent appointment
8 Selected Publications in Pharmaceutical & Medicinal Chemistry, RCSI
1. N-heterocyclic carbene catalysed homoenolate addition to 3-methyl-4-nitro-5-styrylisoxazoles. D. S. Illera, S. Surisetti, M. Moccia, G. Bellini, M. Saviano, M. F. A. Adamo, Tetrahedron Lett., 2012, 53,1808-1811
2. Phase transfer catalyzed enantioselective cyclopropanation of 4-nitro-5-styrylisoxazoles. C. Del Fiandra, L. Piras, F Fini, P. Disetti, M. Moccia, M. F. A. Adamo, Chem. Commun., 2012, 48, 3863-3865
3. Catalytic Enantioselective Addition of Sodium Bisulfite to Chalcones. M. Moccia, F. Fini, M. Scagnetti, M. F. A. Adamo, Angew. Chem., Int. Ed., 2011, 50, 6893-6895
4. Synthesis, structural and conformational properties, and gas phasereactivity of 1,4-dihydropyridine ester and ketone derivatives. G. Giorgi, M. F. A. Adamo, F. Ponticelli, A. Ventura, Org. Biomol. Chem., 2010, 8, 5339-5344
5. Alkynyl-2-deoxy-d-riboses, a cornucopia for the generation of families of C-nucleosides. M. F. A. Adamo, R. Pergoli and M. Moccia, Tetrahedron, 2010, 66, 9242-9251
6. Development of a Mild Procedure for the Addition of Bisulfite to Electrophilic Olefins. F. Fini, M. Nagabelli, M. F. A. Adamo, Adv. Synth. Catal., 2010, 352, 3163-3168
7. Catalytic asymmetric conjugate addition of nitroalkanes to 4-nitro-styrylisoxazoles. A. Baschieri, L. Bernardi, A. Ricci, S. Suresh, M. F. A. Adamo, Angew. Chem. Int., Ed. 2009, 48, 9342-9345
8. Reaction of 5-(1-bromo-2-arylvinyl)-3-methyl-4-nitroisoxazoles and 1,3-dicarbonyl compounds. M. F. A. Adamo, S. Suresh, L. Piras, Tetrahedron, 2009, 65, 5402-5408
9. Preparation of functionalised monobactams from pyridones. M. F. A. Adamo, P. Disetti, L. Piras, Tetrahedron Lett., 2009, 50, 3580-3584. (50
th anniversary special issue, invited contribution)
10. Synthesis of homochiral dihydroxy-4-nitroisoxazolines via one-pot asymmetric dihydroxylation-reduction. M. F. A. Adamo, M. Nagabelli, Org. Lett., 2008, 10, 1807-1810
11. The prevalence of metal-based drugs as therapeutic or diagnostic agents: beyond platinum. D. Gaynor, D. M. Griffith, Dalton Trans., 2012, 41, 13239-13257 (Perspective – also Cover Page)
12. Valuable Insight into the Anti-Cancer Activity of the Platinum-Histone Deacetylase Inhibitor Conjugate, cis-Pt(NH3)2malSAHA-2H)]. V. Brabec, D.M.Griffith, A. Kisova, H. Kostrhunova, Z. Lenka, Z, C.J. Marmion, J. Kasparkova, Mol. Pharmaceutics, 2012, 9, 1990–1999
13. Novel trans-platinum complexes of the histone deacetylase inhibitor valproic acid; synthesis, in vitro cytotoxicity and mutagenicity. D.M.Griffith, B. Duff, K.Y. Suponitsky, K. Kavanagh, M.P. Morgan, D. Egan, C.J. Marmion. J. Inorg. Biochem., 2011, 105, 793-799.
14. Suberoylanilide hydroxamic acid, a potent histone deacetylase inhibitor; its X-ray crystal structure and solid state and solution studies of its Zn(II), Ni(II), Cu(II) and Fe(III) complexes. D.M. Griffith, B. Szocs, T. Keogh, K.Y. Suponitsky, E. Farkas, P. Buglyó, C.J.Marmion, J. Inorg. Biochem. 2011, 105, 763-769.
15. Enzyme inhibition as a key target for the development of novel metal-based anti-cancer therapeutics. D.M.Griffith, J.Parker, C.J. Marmion. Anti-Cancer Agents Med. Chem., 2010, 10, 354-370 (special issue, invited contribution).
16. A Novel Anti-Cancer Bifunctional Platinum Drug Candidate with Dual DNA Binding and Histone Deacetylase Inhibitory Activity. D.M. Griffith, M.P. Morgan, C.J. Marmion. Chem. Commun., 2009, 44, 6735-6737. (Selected as a ‘Hot Article' by the Editor).
17. The reduction of platinum(IV) and palladium(IV) ions by 2,6-pyridinedihydroxamic acid. D. Griffith, A. Chopra, H. Müller-Bunz, C. J. Marmion, Dalton Trans., 2008, 6933-6939.
18. Ruthenium(III) dimethylsulfoxide pyridinehydroxamic acid complexes as potential anti-metastatic agents; synthesis, characterisation and in vitro pharmacological evaluation. D. Griffith, S. Cecco, E. Zangrando, A. Bergamo, G. Sava and C. J. Marmion, J. Biol. Inorg. Chem., 2008, 13, 511-520.
19. Monohydroxamic acids and bridging dihydroxamic acids as chelators to ruthenium(III) and as nitric oxide donors; synthesis, speciation studies and nitric oxide releasing investigation. D. Griffith, K. Krot, J. Commiskey, K.B. Nolan and C.J. Marmion, Dalton Trans., 2008, 137-147.
20. Iron(III) tris(pyridinehydroxamate)s and related nickel and zinc complexes: platforms for the design of novel heterobimetallic supramolecular assemblies. C. Mulcahy, K.A. Krot, D.M. Griffith, K.Y. Suponitsky, Z.A. Starikova, C.J. Marmion, , Eur. J. Inorg. Chem., 2007, 1373-1380.
21. Synthesis, characterisation and speciation studies of heterobimetallic pyridinehydroxamate-bridged Pt(II)/M(II) complexes (M = Cu, Ni, Zn). Crystal structure of a novel heterobimetallic 3-pyridinehydroxamate-bridged Pt(II)/Cu(II) wave-like
coordination polymer. C. Mulcahy, Fedor M. Dolgushin, K.A. Krot, D. Griffith and C. J. Marmion, Dalton Trans., 2005, 1993-1998.
23. Inhibition of platelet adhesion by peptidomimetics mimicking the interactive β-hairpin of glycoprotein Ibα. E. Bernard, V. Buckley, E. Moman, L. Coleman, G. Meade, D. Kenny, M. Devocelle, Bioorg. Med. Chem. Lett., 2012, 22, 323-326.
24. -Lactam-host defence peptide conjugates as antibiotic prodrug candidates targeting resistant bacteria. S. Desgranges, C. C. Ruddle, L. P. Burke, T. M. McFadden, J. E. O’Brien, D. Fitzgerald-Hughes, H. Humphreys, T. P. Smyth, M. Devocelle, RSC Adv., 2012, 2, 2480-2492.
25. Synthesis of Mutual Azo Prodrugs of Anti-inflammatory Agents and Peptides Facilitated by α-Aminoisobutyric Acid. D. A. Kennedy, N. Vembu, F. R. Fronczek, M. Devocelle, J Org Chem. 2011, 76, 9641-9647.
26. In Vitro Activities against Cystic Fibrosis Pathogens of Synthetic Host Defence Propeptides Processed by Neutrophil Elastase. S. Desgranges, F. Le Prieult, A. Daly, J. Lydon, M. Brennan, D. K. Rai, A. P. Subasinghage, C. M. Hewage, S.-A. Cryan, C. Greene, N. G. McElvaney, T. P. Smyth, D. Fitzgerald-Hughes, H. Humphreys, M. Devocelle, Antimicrob Agents Chemother. 2011 55, 2487-2489.
27. Multimodal Cell Imaging by Ruthenium Polypyridyl Labelled Cell Penetrating Peptides. L. Cosgrave, M. Devocelle, R. J. Forster, T. E. Keyes, Chem. Commun. 2010, 46, 103-105.
28. A Computational Model of Antibiotic-Resistance Mechanisms in Methicillin-Resistant Staphylococcus aureus (MRSA). J. Murphy, R. Walshe, M. Devocelle, J Theor Biol, 2008, 254, 284-293.
29. Bioinformatic discovery of novel bioactive peptides. R. J. Edwards, N. Moran, M. Devocelle, A. Kiernan, G. Meade, W. Signac, M. Foy, S. D. E. Park, E. Dunne, D. Kenny, D. C. Shields, Nat Chem Biol, 2007, 3, 108-112.
30. Parallel synthesis and in vitro activity of novel anthranilic hydroxamate-based inhibitors of the Prostaglandin H2 Synthase peroxidase activity. J. Lee, A. J. Chubb, E. Moman, B. M. McLoughlin, C. T. Sharkey,J. G. Kelly, K. B. Nolan, M. Devocelle, D. J. Fitzgerald, Org. Biomol. Chem., 2005, 3, 3678 - 3685.
31. A Convenient Parallel Synthesis of Low Molecular Weight Hydroxamic Acids Using Polymer-supported 1-Hydroxybenzotriazole. M. Devocelle, B. M.McLoughlin, C.T.Sharkey, D.J.Fitzgerald, K.B. Nolan, Org. Biomol. Chem., 2003, 1, 850 - 853.
32. Synthesis and evaluation of phosphoramidate and phosphorothioamidate analogues of amiprophos methyl as potential antimalarial agents. C. Mara, E. Dempsey, A. Bell, J. W. Barlow, Bioorg Med. Chem. Letts., 2011, 21, 6180-6183.
33. Synthesis of novel mast cell-stabilising and anti-allergic 1,2,3,4-tetrahydro-1-naphthalenols and related compounds. J. W. Barlow, A. P. McHugh, O. Woods, J. J. Walsh. Eur. J. Med. Chem., 2011, 46, 1545-1554.
34. Novel Mast Cell-Stabilising Amine Derivatives of 3,4-Dihydronaphthalen-1(2H)-one and 6,7,8,9-Tetrahydro-5H-benzo[7]annulen-5-one. J. W. Barlow, T. Zhang, O. Woods, A. J. Byrne, J. J. Walsh, Med. Chem., 2011, 7, 213-223.
35. Synthesis and pharmacological evaluation of the individual stereoisomers of 3-[methyl(1,2,3,4-tetrahydro-2-naphthalenyl)amino]-1-indanone, a potent mast cell stabilising agent. A. J. Byrne, J. W. Barlow, J. J. Walsh, Bioorg. Med. Chem. Letts., 2011, 21, 1191-1194.
36. Screening of siRNA nanoparticles for delivery to airway epithelial cells using high-content analysis. A. Hibbitts, N. Lieggi, O. McCabe, W. Thomas, J. W. Barlow, F O’Brien, S. A. Cryan, Therapeutic Delivery, 2011, 2, 987-999.
37. Evaluation of the ability of pharmacy and medicine students to calculate drug dosage. L. Meyler, Z. Ramtoola, J. W. Barlow. Pharmacy Education, 2011, 11, 186 – 189.
38. Synthesis and evaluation of dimeric 1,2,3,4-tetrahydro-naphthalenylamine and indan-1-ylamine derivatives with mast cell-stabilising and anti-allergic activity. J. W. Barlow, J. J. Walsh, Eur. J. Med. Chem., 2010, 45, 25-37. 35.
39. Microtubules as antiparasitic drug targets. B. J. Fennell, J. A. Naughton J. W. Barlow, G. Brennan, I. Fairweather, E. Hoey, N. McFerran, A. Trudgett A. Bell, Expert Opin. Drug Discov. 2008, 3, 501-518.
40. Synthesis and evaluation of 4-amino-3,4-dihydro-2H-naphthalen-1-one derivatives as mast cell stabilising and anti-inflammatory compounds. J. W. Barlow, J. J. Walsh, Eur. J. Med. Chem., 2008, 43, 2891-2900.
41. Teaching and assessment of an innovative and integrated pharmacy undergraduate module. J. W. Barlow, J. Strawbridge.
Pharmacy Education, 2007, 7, 193-195.
42. Metal complexes of cyclic hydroxamates. Synthesis and crystal structures of
3-hydroxy-2- methyl- 3H-quinazolin-4-one (ChaH) and of its Fe(III), Co(II), Ni(II), Cu(II) and Zn(II) complexes. A. Alagha, L.
Parthasarathi, D. Gaynor, H. Muller-Bunz , Z. A. Starikova, E. Farkas, E. C. O’Brien, M-J Gil and K. B. Nolan. Inorg Chim Acta,
2011, 368, 58-66.
43. Monohydroxamic acids and bridging dihydroxamic acids as chelators to ruthenium(III) and as nitric oxide donors: syntheses, speciation studies and nitric oxide releasing investigation. D. Griffith, K. Krot, J. Comiskey, K. B. Nolan, C. J. Marmion, Dalton Trans, 2008, 137-147.
44. The Productive Conformation of PGG2 at the Peroxidase Site of Prostaglandin Endoperoxide H Synthase. A. J. Chubb, D. J. Fitzgerald, K. B. Nolan, E. Moman, Biochemistry, 2006, 45, 811-820.
45. Calix(4)arene pyridine derivative and its monomeric component: Structural and thermodynamic aspects of their complexation with metal cations,, A. F.Danil de Namor, A. Aguilar-Cornejo, R. Soualhi, M. Shehab, K.B. Nolan, N.Ouazzani, L. Mandi, J. Phys. Chem., 2005, 109, 14795 -14799.
46. Hydroxamic acids - an intriguing family of bioligands and enzyme inhibitors. C.J. Marmion, D.Griffith, K.B. Nolan, Eur. J. Inorg. Chem., 2004, 15, 3003-3016.
47. Synthesis, structures and speciation studies of ruthenium(III)-hydroxamate/ hydroximato complexes. Crystal and molecular structure of hydrated [Ru(H2edta)(2-methoxyphenylhydroxamate)], the first structurally characterised ruthenium (III)-hydroxamate complex. J Comiskey, E. Farkas, K. A. Krot-Lacina, R. G. Pritchard, C. A. McAuliffe (the late) and K. B. Nolan, Dalton Trans., 2003, 4243 - 4249.
48. A novel family of hydroxamate based acylating inhibitors of cyclooxygenase. C. M. Dooley, M. Devocelle, B. McLoughlin, K. B. Nolan and D. J. Fitzgerald, Mol. Pharmacol. 2003, 63, 450-455.
49. Synthesis and structure of a heptanuclear nickel(II) complex uniquely exhibiting four distinct binding modes, two of which are novel, for a hydroxamate ligand, D. Gaynor, Z. A. Starikova, S. Ostrovsky, W. Haase, K. B. Nolan, Chem. Commun., 2002, 506-507.
50. Ruthenium(III) readily abstracts NO from L-arginine, the physiological precursor to NO, in the presence of H2O2. A remarkably simple model system for NO synthases, C. J. Marmion, T. Murphy, K.B. Nolan, Chem. Commun., 2001, 1870-1871.
51. Copper(II) complexes of isomeric aminophenylhydroxamic acids. A novel 'clam-like' dimeric metallacrown and polymeric helical structure containing interlinked unique copper(II) sites, D. Gaynor, Z. A. Starikova, W. Haase, K. B. Nolan, Dalton Trans., 2001, 1578-1581.
52. O-Acetylsalicylhydroxamic acid, a novel acetylating inhibitor of prostaglandin H-2 -synthase: Structural and functional characterization of enzyme-inhibitor interactions. P. J. Loll, C. T. Sharkey, S. J. O'Connor, C. M. Dooley, E. O'Brien, M. Devocelle, K. B. Nolan, B. S. Selinsky and D. J. Fitzgerald, Mol. Pharmacol., 2001, 60, 1407-1413.
